Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Haematologica
Andrew SpencerMaría-Victoria Mateos

Abstract

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0-27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P<0.0001) and improved the overall response rate (83.8% versus 63.2%; P<0.0001) compared with bortezomib and dexamethasone alone. The progression-free survival benefit of daratumumab plus bortezomib and dexamethasone was most apparent in patients with 1 prior line of therapy (median: not reached versus 7.9 months; hazard ratio, 0.19; 95% con fidence interval, 0.12-0.29; P<0.0001). Daratumumab plus bortezomib and dexamethasone was also superior to bortezomib and dexamethasone alone in subgroups based on prior treatment exposure (bortezomib, thalidomide, or lenalidomide), lenalidomide-refractory status, time since last therapy (≤12, >12, ≤6, or >6 month...Continue Reading

Citations

Jan 24, 2019·Current Hematologic Malignancy Reports·Shalin KothariSarah A Holstein
May 23, 2019·International Journal of Hematology·Reham AshourShinsuke Iida
May 30, 2019·The New England Journal of Medicine·Thierry FaconUNKNOWN MAIA Trial Investigators
Jun 30, 2019·Expert Review of Hematology·Massimo MartinoMassimo Gentile
Aug 1, 2019·British Journal of Haematology·Susan BalLuciano J Costa
Nov 5, 2019·Expert Review of Anticancer Therapy·Evangelos Eleutherakis-PapaiakovouMeletios A Dimopoulos
Oct 2, 2019·Journal of Clinical Medicine·Ana P Gonzalez-RodriguezSegundo Gonzalez
Jan 17, 2020·Expert Opinion on Biological Therapy·Ioannis Ntanasis-StathopoulosEvangelos Terpos
Jul 13, 2019·Blood·Michele Cavo
Dec 24, 2019·Expert Review of Anticancer Therapy·Albert OriolAlicia Senin
Mar 7, 2020·Cells·Cinnie Yentia SoekojoWee Joo Chng
Apr 16, 2020·Expert Review of Hematology·Mehmet H Kocoglu, Ashraf Z Badros
Apr 26, 2020·Journal of Clinical Medicine·Laurens E FranssenInger S Nijhof
Jun 20, 2020·European Journal of Haematology·Fredrik Schjesvold
Jul 11, 2020·Journal of Clinical Medicine·Roberto MinaMario Boccadoro
Jul 29, 2020·Blood Research·Ji Hyun Lee, Sung-Hyun Kim
Aug 29, 2019·Leukemia·Abdul Hamid BazarbachiMohamad Mohty
Sep 3, 2020·Future Oncology·Semira SheikhSuzanne Trudel
May 28, 2019·Expert Review of Hematology·Nicola GiulianiFabio Malavasi
Mar 22, 2019·Blood Cancer Journal·Philippe MoreauMaria-Victoria Mateos
Nov 30, 2019·Journal of Oncology·Hiroko Nishida, Taketo Yamada
Nov 7, 2019·Molecular Cancer·Quande LinDelong Liu
Sep 10, 2020·Cancer Management and Research·Danai DimaCindy Varga
Sep 16, 2020·Journal of Personalized Medicine·Alessandro GozzettiMonica Bocchia
Aug 29, 2019·Journal of Managed Care & Specialty Pharmacy·Sarah HollmannEric M Maiese
Jan 17, 2020·Cancers·Despina FotiouEvangelos Terpos
Apr 1, 2020·Journal of Clinical and Experimental Hematopathology : JCEH·Masuho SaburiToshiyuki Nakayama
Aug 14, 2019·Journal of Cancer Research and Clinical Oncology·M A BaertschH Goldschmidt
Apr 10, 2019·International Journal of Hematology·Hiroki KobayashiKosei Matsue

❮ Previous
Next ❯

Software Mentioned

POLLUX
CASTOR

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.